Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) insider Samuel C. Blackman sold 10,000 shares of the company's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $16.10, for a total value of $161,000.00. Following the completion of the sale, the insider now owns 1,057,535 shares of the company's stock, valued at $17,026,313.50. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Day One Biopharmaceuticals Stock Performance
Shares of DAWN opened at $15.64 on Wednesday. The firm's 50-day simple moving average is $14.43 and its 200 day simple moving average is $14.41. Day One Biopharmaceuticals, Inc. has a 52 week low of $10.90 and a 52 week high of $18.07. The firm has a market cap of $1.58 billion, a P/E ratio of -15.18 and a beta of -1.51.
Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.58. The company had revenue of $93.76 million during the quarter, compared to analyst estimates of $15.05 million. During the same period in the prior year, the firm earned ($0.54) earnings per share. As a group, equities analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.97 earnings per share for the current year.
Institutional Investors Weigh In On Day One Biopharmaceuticals
Trump’s Sending THIS Crypto Higher on Purpose
From Crypto 101 Media | Ad
Discover the coin set to explode before 2025!
Trump could trigger THIS crypto coin…
YES, I WANT THE #1 CRYPTO NOW
A number of large investors have recently modified their holdings of DAWN. Deerfield Management Company L.P. Series C grew its stake in shares of Day One Biopharmaceuticals by 65.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company's stock worth $40,281,000 after buying an additional 1,157,825 shares during the last quarter. First Turn Management LLC acquired a new stake in shares of Day One Biopharmaceuticals during the third quarter worth $13,204,000. Estuary Capital Management LP grew its holdings in Day One Biopharmaceuticals by 82.5% during the 1st quarter. Estuary Capital Management LP now owns 1,611,137 shares of the company's stock worth $26,616,000 after acquiring an additional 728,240 shares during the period. Ally Bridge Group NY LLC acquired a new stake in Day One Biopharmaceuticals during the second quarter worth approximately $7,387,000. Finally, Point72 Asset Management L.P. bought a new position in shares of Day One Biopharmaceuticals in the second quarter valued at $6,480,000. Institutional investors and hedge funds own 87.95% of the company's stock.
Analyst Upgrades and Downgrades
DAWN has been the subject of a number of analyst reports. Wedbush restated an "outperform" rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a report on Thursday, July 25th. Needham & Company LLC reissued a "buy" rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. TD Cowen raised Day One Biopharmaceuticals to a "strong-buy" rating in a research report on Monday, November 4th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. Finally, JPMorgan Chase & Co. reduced their price target on Day One Biopharmaceuticals from $38.00 to $36.00 and set an "overweight" rating for the company in a research report on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $35.71.
Get Our Latest Report on Day One Biopharmaceuticals
About Day One Biopharmaceuticals
(
Get Free Report)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
